{
  "id": "40",
  "title": "Persistent regulatory memory",
  "summary": "A persistent gene-regulatory state may sustain nerve injury after the initiating diabetic exposure improves.",
  "source_title": "Persistent gene regulation sustains injury after the exposure improves",
  "page": "40_epigenetic_memory.html",
  "source_markdown": "sources/40_epigenetic_memory.md",
  "structured_data": "data/40_epigenetic_memory.json",
  "snapshot_date": "2026-09-14",
  "source_review_date": "2026-09-13",
  "scope_label": "After exposure improves",
  "scope_exception": true,
  "source_headline_markdown": "**Base judgment: 3.3%; skeptical–optimistic sensitivity: 0.1%–30.6%.** Subjective probabilities of the causal proposition below, not effect sizes. Decimal places only show arithmetic. Reviewed 13 September 2026. [Probability method](probability_method.md) · [Collection index](README.md).",
  "probability_percent": {
    "skeptical": 0.0875,
    "base": 3.290625,
    "favorable": 30.6
  },
  "probability_meaning": "Subjective belief in the complete causal proposition. Scenario endpoints are sensitivity products, not confidence limits.",
  "causal_proposition_markdown": "Past diabetic exposure installs a persistent gene-regulatory state in peripheral neurons or supporting cells that continues to drive axon injury after current glycemia improves.\n\n**Scope:** Exception: diabetes after a sustained improvement in glycemia, with a five-year injury/progression endpoint. The subgroup threshold refers to neuropathy cases in this post-improvement population. This is persistence of a harmful mediator, not the mere clinical fact that earlier control has lasting benefits.\n\n**Causal role:** persistent amplification or failed recovery. Unless the scope specifies an exception, materiality means at least 20% less five-year net terminal loss in an identifiable subgroup representing at least 10% of incident DPN cases in the stated population. The target remains human peptidergic C-fibers when a study measures a broader endpoint.",
  "claims": [
    {
      "id": "R1",
      "source_id": "1",
      "claim": "Diabetic exposure creates a persistent regulatory state in relevant peripheral cells.",
      "claim_markdown": "Diabetic exposure creates a persistent regulatory state in relevant peripheral cells.",
      "conditional_percent": {
        "skeptical": 35.0,
        "base": 65.0,
        "favorable": 85.0
      },
      "cumulative_base_percent": 65.0,
      "source_cumulative_display": "65.0%",
      "reason_markdown": "Human blood epigenetics support exposure memory, not target-cell causation.",
      "question": "Does diabetic exposure create a persistent gene-regulatory state in peripheral neurons or supporting cells?"
    },
    {
      "id": "R2",
      "source_id": "2",
      "claim": "The state persists independently of current exposure and cell-composition changes.",
      "claim_markdown": "The state persists independently of current exposure and cell-composition changes.",
      "conditional_percent": {
        "skeptical": 25.0,
        "base": 50.0,
        "favorable": 80.0
      },
      "cumulative_base_percent": 32.5,
      "source_cumulative_display": "32.5%",
      "reason_markdown": "Cross-sectional methylation cannot establish persistence within the same cells.",
      "question": "Does the gene-regulatory state persist independently of current exposure and changes in cell composition?"
    },
    {
      "id": "R3",
      "source_id": "3",
      "claim": "It sustains a harmful effector rather than marking history or supporting adaptation.",
      "claim_markdown": "It sustains a harmful effector rather than marking history or supporting adaptation.",
      "conditional_percent": {
        "skeptical": 20.0,
        "base": 45.0,
        "favorable": 75.0
      },
      "cumulative_base_percent": 14.625,
      "source_cumulative_display": "14.6%",
      "reason_markdown": "The relevant neuronal/glial effector has not been isolated.",
      "question": "Does the persistent state sustain a harmful biological activity, beyond recording exposure history or supporting adaptation?"
    },
    {
      "id": "R4",
      "source_id": "4",
      "claim": "The effector causes new peptidergic structural loss after glycemia improves.",
      "claim_markdown": "The effector causes new peptidergic structural loss after glycemia improves.",
      "conditional_percent": {
        "skeptical": 20.0,
        "base": 45.0,
        "favorable": 75.0
      },
      "cumulative_base_percent": 6.58125,
      "source_cumulative_display": "6.6%",
      "reason_markdown": "Legacy damage and reduced reserve are strong alternative explanations.",
      "question": "Does harmful activity sustained by persistent gene regulation cause new peptidergic structural loss after glycemia improves?"
    },
    {
      "id": "R5",
      "source_id": "5",
      "claim": "Removing the persistent state would materially reduce that loss.",
      "claim_markdown": "Removing the persistent state would materially reduce that loss.",
      "conditional_percent": {
        "skeptical": 25.0,
        "base": 50.0,
        "favorable": 80.0
      },
      "cumulative_base_percent": 3.290625,
      "source_cumulative_display": "3.3%",
      "reason_markdown": "Selective human mediation and population magnitude remain unknown.",
      "question": "Would removing the persistent regulatory state avert at least 20% of five-year terminal loss in a subgroup accounting for at least 10% of neuropathy cases after glycemic improvement?"
    }
  ],
  "sections": [
    {
      "heading": "The causal claim and its scope",
      "markdown": "Past diabetic exposure installs a persistent gene-regulatory state in peripheral neurons or supporting cells that continues to drive axon injury after current glycemia improves.\n\n**Scope:** Exception: diabetes after a sustained improvement in glycemia, with a five-year injury/progression endpoint. The subgroup threshold refers to neuropathy cases in this post-improvement population. This is persistence of a harmful mediator, not the mere clinical fact that earlier control has lasting benefits.\n\n**Causal role:** persistent amplification or failed recovery. Unless the scope specifies an exception, materiality means at least 20% less five-year net terminal loss in an identifiable subgroup representing at least 10% of incident DPN cases in the stated population. The target remains human peptidergic C-fibers when a study measures a broader endpoint."
    },
    {
      "heading": "Reasoning from the biological requirements",
      "markdown": "Clinical metabolic memory can arise from already lost axons, glycated matrix or accumulated exposure without any persistent epigenetic program. This hypothesis additionally needs a durable regulatory state that remains after the initiating exposure is reduced, produces a harmful effector, and continues causing new loss. A stable methylation difference can be a record of exposure rather than its causal carrier. Reversing a gene mark must change injury through that state, not through unrelated drug effects."
    },
    {
      "heading": "Probabilities of the necessary claims",
      "markdown": "Conditional prices are skeptical / base / optimistic. Each price after the first assumes *all earlier requirements are true*. Their order is an order for assessing joint belief, not necessarily a linear biological pathway. The cumulative column uses the base scenario. Temporal order, connected compartments and the causal prevention comparison are included in these requirements, without extra generic multipliers.\n\n| # | Necessary claim | Conditional YES | Cumulative YES | Reason for this judgment |\n|---|---|---:|---:|---|\n| 1 | Diabetic exposure creates a persistent regulatory state in relevant peripheral cells. | 35 / **65** / 85% | 65.0% | Human blood epigenetics support exposure memory, not target-cell causation. |\n| 2 | The state persists independently of current exposure and cell-composition changes. | 25 / **50** / 80% | 32.5% | Cross-sectional methylation cannot establish persistence within the same cells. |\n| 3 | It sustains a harmful effector rather than marking history or supporting adaptation. | 20 / **45** / 75% | 14.6% | The relevant neuronal/glial effector has not been isolated. |\n| 4 | The effector causes new peptidergic structural loss after glycemia improves. | 20 / **45** / 75% | 6.6% | Legacy damage and reduced reserve are strong alternative explanations. |\n| 5 | Removing the persistent state would materially reduce that loss. | 25 / **50** / 80% | 3.3% | Selective human mediation and population magnitude remain unknown. |"
    },
    {
      "heading": "Evidence that moves the judgment",
      "markdown": "- Selected DCCT/EDIC blood monocytes/lymphocytes showed histone-modification associations with glycemic history and complications. This supports human exposure-related epigenetic differences, but is not a peripheral-neuron perturbation or proof of a neuropathy mediator. [Miao et al., 2014](https://pmc.ncbi.nlm.nih.gov/articles/PMC3994951/).\n\n- The repository's public-evidence search did not identify a nerve structural contrast that cleanly separated a persistent glycation/GLO1 mechanism from ongoing exposure and acute rescue. Its GLO1 result demonstrated buffered acute detoxification, not persistence after washout or glucose normalization. [Prior correction](../../../findings/aug13_glycation_memory_glo1_epistasis_no_go.md)."
    },
    {
      "heading": "Why these odds and how uncertain they are",
      "markdown": "The broad fact of lasting consequences of diabetes is credible, but epigenetic mediation is a much narrower proposition. The price is low because exposure history, cell composition and irreversible prior damage explain many of the same observations. A compelling molecular mark needs a damaging downstream function and ongoing new injury, not just longitudinal stability.\n\nThe skeptical scenario treats marks as records and clinical persistence as legacy damage. The optimistic scenario assumes a reversible harmful state in a definable cell population. Existing human blood evidence offers little precision about which peripheral neuron/glial program, if any, carries the effect.\n\nConditional inputs: base **[65, 50, 45, 45, 50]%**; skeptical **[35, 25, 20, 20, 25]%**; optimistic **[85, 80, 75, 75, 80]%**. Products give the headline prices. The span measures sensitivity to these interpretations; it is not a statistical confidence interval.\n\n**Numerical update example:** Public evidence linking a persistent regulatory state to a specific harmful effector after exposure normalization would strengthen requirement 3; a stable mark with no functional effect would weaken it. Changing only requirement 3 from 45% to 80% raises the whole price to **5.9%**; reducing it to 10% lowers the price to **0.7%**. These are hypothetical evidence updates. Even resolving that one requirement with certainty would leave a complete price of 7.3% if the others stayed unchanged."
    },
    {
      "heading": "Overlap and boundary",
      "markdown": "Distinct from persistent [matrix glycation](03_extracellular_matrix_glycation.md), [senescence](33_senescence_sasp.md) and current [inflammation](19_tnf_tlr4_inflammation.md). The [metabolic-memory topic](../../../knowledge/topics/metabolic-memory.md) records related negative analyses; missing identification is not biological disproof."
    }
  ],
  "source_claim_table_markdown": "| # | Necessary claim | Conditional YES | Cumulative YES | Reason for this judgment |\n|---|---|---:|---:|---|\n| 1 | Diabetic exposure creates a persistent regulatory state in relevant peripheral cells. | 35 / **65** / 85% | 65.0% | Human blood epigenetics support exposure memory, not target-cell causation. |\n| 2 | The state persists independently of current exposure and cell-composition changes. | 25 / **50** / 80% | 32.5% | Cross-sectional methylation cannot establish persistence within the same cells. |\n| 3 | It sustains a harmful effector rather than marking history or supporting adaptation. | 20 / **45** / 75% | 14.6% | The relevant neuronal/glial effector has not been isolated. |\n| 4 | The effector causes new peptidergic structural loss after glycemia improves. | 20 / **45** / 75% | 6.6% | Legacy damage and reduced reserve are strong alternative explanations. |\n| 5 | Removing the persistent state would materially reduce that loss. | 25 / **50** / 80% | 3.3% | Selective human mediation and population magnitude remain unknown. |"
}